SBH
LCTX icon

Segall Bryant & Hamill’s Lineage Cell Therapeutics LCTX Stock Holding History

Segall Bryant & Hamill’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,974
Closed -$20K – 844
2019
Q2 		$20K Buy
+17,974
New +$20.7K ﹤0.01% 808
2019
Q1 		– Sell
-13,383
Closed -$12K – 850
2018
Q4 		$12K Buy
+13,383
New +$20.5K ﹤0.01% 816

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Segall Bryant & Hamill's LCTX Position: Q3 2019 in Review

Segall Bryant & Hamill sold out of Lineage Cell Therapeutics (LCTX) in Q3 2019, closing a stake of 17,974 shares — an estimated $20K sold.

Segall Bryant & Hamill first reported a position in LCTX in Q4 2018 and held it in 2 quarters. The position peaked at $20K in Q2 2019. 96 funds tracked by Wall St. Rank hold LCTX as of Q3 2019.

  • Segall Bryant & Hamill reported no remaining Lineage Cell Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Segall Bryant & Hamill sold 17,974 Lineage Cell Therapeutics shares in Q3 2019, an estimated $20K.
  • Segall Bryant & Hamill first reported a position in Lineage Cell Therapeutics in Q4 2018 and held it in 2 quarters.
  • Segall Bryant & Hamill's Lineage Cell Therapeutics position peaked at $20K in Q2 2019.
  • 96 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2019.

Based on Segall Bryant & Hamill's 13F filing for Q3 2019, filed 12 Nov 2019.